Targets › CD34
9 programs from 9 companies in 10 trials: 10 Phase 1; Oncology, Genitourinary, Other; next expected readout Dec 2026.
Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. (UniProt, P28906)
Open in Phaseline: the race on CD34, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Paul Szabolcs | autologous CD34-selected peripheral blood stem cells transplant CD34-selected hematopoietic stem cell transplantation | CD34 | Phase 1 | Crohn's Disease | Dec 2026 |
| Jeffrey Veale, MD | CD34+ and CD3+ hematopoietic stem/progenitor cells Donor-derived blood stem and T cells for facilitating mixed chimerism and immune tolerance | CD34, CD3E | Phase 1 | Renal Transplant Rejection | May 2027 |
| Francisco Hernández Oliveros | CD34+ enriched, naïve T cell-depleted hematopoietic graft supplemented with memo Hematopoietic stem cell transplantation with selective lymphocyte composition to promote i | CD34 | Phase 1 | Solid Organ Transplant Complications | Jun 2028 |
| Stanford University | Donor Hematopoietic Stem Cells and Recipient Tregs Donor CD34+ hematopoietic stem cells combined with recipient regulatory T cells to facilit | CD34, IL2RA | Phase 1 | Glioma of Spinal Cord; Living Donor Kidney Transplantation | Jul 2028 |
| Columbia University | CD34+ stem cells from donor bone marrow Infusion of CD34+ hematopoietic stem cells to promote mixed chimerism and reduce rejection | CD34 | Phase 1 | Intestinal Transplantation | Dec 2028 |
| University of Alabama at Birmingham | CD34 selected hematopoietic stem cells CD34+ cell selection and enrichment from hematopoietic stem cell graft | CD34 | Phase 1 | AML | Oct 2029 |
| Diane George | CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) CD34+ cell selection device for T-cell depletion from peripheral blood stem cell transplan | CD34, CD3 | Phase 1 | Bone Marrow Failure Syndrome | Feb 2030 |
| University of Florida | exHSC (ex vivo expanded CD34+ hematopoietic stem cells) Ex vivo expanded CD34+ hematopoietic stem cells | CD34 | Phase 1 | Recurrent High-grade Glioma | Dec 2030 |
| Melody Smith | Orca-T Purified donor-derived regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells | CD34 | Phase 1 | Lymphoid Leukemia | Dec 2045 |
Bone Marrow Failure Syndrome (1) Lymphoid Leukemia (1) Renal Transplant Rejection (1) Crohn's Disease (1) AML (1) Glioma of Spinal Cord (1) Living Donor Kidney Transplantation (1) Solid Organ Transplant Complications (1) Recurrent High-grade Glioma (1) Intestinal Transplantation (1)
other (5), mixed (3), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.